Sexual Health Peptides
FDA-approved and investigational compounds for sexual desire regulation and response.
Showing 2 peptides with evidence-ranked profiles.
PT-141 (Bremelanotide) is an FDA-approved peptide medication marketed as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors like Viagra, PT-141 works through the central nervous system by activating melanocortin receptors involved in sexual arousal. Clinical trials demonstrated significant improvements in sexual desire and satisfaction.
Melanotan II is a synthetic analog of alpha-melanocyte stimulating hormone that binds to melanocortin receptors. Originally developed for skin tanning protection against UV damage, it was found to have significant effects on sexual arousal and erectile function. Development was discontinued due to side effects and regulatory concerns. It is not FDA-approved.